Background: Comorbid autoimmune disorders are increasingly recognized in multiple sclerosis (MS), yet their integrated management remains a clinical challenge.
Report: A 28-year-old female with MS was diagnosed with ulcerative colitis (UC). Upon initiation of cladribine therapy for MS, she achieved a state of UC remission: 4 years later, she experienced a relapse of both conditions and was treated with ozanimod, approved for MS (2020) and UC (2021).
Discussion: This case highlights cladribine's potential in managing both MS and UC, though its efficacy faded over time. Further research into shared immunopathogenesis and therapeutic strategies in co-existing autoimmune diseases is warranted.
Keywords: Case report; cladribine; multiple sclerosis; ulcerative colitis.